SHINE studie

Titel:  A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma

Studie is gesloten

• Protocol (intranet)
• Patienteninformatie

Studiemedicatie: Ibrutinib

Medicatorprotocol beschikbaar: volgt

Verpleegkundige documenten

• Kliniek: volgt
• Poliklinieknvt
• Huisartsenbrief:nvt

Aanmelden patienten via trialbureau hematologie (sein 59255, hemat.trial@amc.nl)